← Back to patent-cliff list
达格列净丙二醇/盐酸二甲双胍
Tier A — Act nowDapagliflozin Propanediol/Metformin Hydrochloride · all drugs expiring in 2030 →
阿斯利康
Originator
2014
First approval
2030
Expiry (public)
$5.6B *
Peak sales
化学药
Type
Targets：PRKAB1、SGLT2
Brand：Ebymect、Xigduo Xr、Xigduo
Indications (approved)：二型糖尿病
Regional status
US
批准上市
2014-10-29
EU
批准上市
2014-01-16
China
批准上市
2023-06-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dapagliflozin Propanediol/Metformin Hydrochloride?
Approved indications include: 二型糖尿病.
When does the Dapagliflozin Propanediol/Metformin Hydrochloride patent expire?
Based on public sources, the Dapagliflozin Propanediol/Metformin Hydrochloride patent expires in 2030.
How do I get a quote for Dapagliflozin Propanediol/Metformin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24